MedTrace Logo

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

NCT06554184 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 706

Last updated 2025-11-17

No results posted yet for this study

Summary

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Conditions

  • Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Interventions

DRUG

HR20013 + dexamethasone + palonosetron placebo

HR20013 + dexamethasone + palonosetron placebo

DRUG

Palonosetron + dexamethasone + HR20013 placebo

Palonosetron + dexamethasone + HR20013 placebo

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2025-07-28
Completion
2025-10-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554184 on ClinicalTrials.gov